logo
Pediatric Dentistry Kahala Announces Its New Hybrid-Responsive Website

Pediatric Dentistry Kahala Announces Its New Hybrid-Responsive Website

Yahoo26-03-2025

HONOLULU, March 26, 2025 /PRNewswire/ -- Pediatric Dentistry Kahala is thrilled to introduce its new website at https://www.pediatricdentistrykahala.com. The updated website has been optimized for viewing on any platform. The hybrid responsive design allows families to access information on their children's oral health at home or on the go. With bright colors and an engaging aesthetic, the website reflects the practice's commitment to caring for the youngest patients and their families.
Dr. Audrey Rawson leads the practice with compassion and expertise. She is Board-certified and a Diplomate with the American Board of Pediatric Dentistry. Her unique background includes training in general dentistry, pediatric dentistry, and early childhood education. She received both her undergraduate and dental degrees from the University of California, Los Angeles.
Dr. Allen Hirai brings 30 years of experience to the practice. After receiving his D.D.S. from the University of the Pacific, the doctor completed a rigorous Pedodontic Clinical Residency at the University of Illinois at Chicago Medical Center. Dr. Hirai specializes in managing children's behavior without the use of sedating medications. He engages children in their care and makes a dental visit an educational experience.
Pediatric Dentistry Kahala specializes in comprehensive oral health care from infancy through the teen years. The practice also treats special-needs patients with the understanding that these children deserve care tailored to their oral health and development.
The practice is proud that it often receives top honors in Honolulu Magazine's Best Dentists in Hawaii. Recognition as a top pediatric dentistry practice reflects its commitment to children.
"We are thrilled to introduce our new website to our parents and guardians," says Dr. Rawson. "We believe that education is a cornerstone of oral health, and we hope that our patients and their families feel engaged and supported when they visit our website."
Pediatric Dentistry Kahala provides the following dental services:
Tooth Eruption & Shedding
Early Dental Care
Preventive & Diagnostic Services
Cosmetic Services
Restorative Services
Sedation
Special Needs Dentistry
Orthodontics
Emergency Dentistry
About Pediatric Dentistry Kahala
Pediatric Dentistry Kahala is a comprehensive dental practice for children of all ages. From babies with their first tooth to their teen years, the practice provides quality care in a child-friendly atmosphere. The practice is located at 4211 Waialae Avenue, Suite 201, Honolulu, HI 96816. To learn more, call 808-737-0076 or visit https://www.pediatricdentistrykahala.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/pediatric-dentistry-kahala-announces-its-new-hybrid-responsive-website-302408052.html
SOURCE Pediatric Dentistry Kahala

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health
Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Yahoo

time37 minutes ago

  • Yahoo

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

Agreement supports the upcoming launch of LYMPHIR for the treatment of cutaneous T-cell lymphoma CRANFORD, N.J., June 9, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH), a leading provider of pharmaceutical and specialty pharmaceutical distribution services in the United States. This agreement is designed to help provide access to LYMPHIR™ (denileukin diftitox-cxdl), an innovative immunotherapy FDA-approved for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), in support of its anticipated U.S. commercial launch. "This agreement marks a key step forward in our launch readiness efforts," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. "Cardinal Health's proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as we work to build a robust commercial distribution network." Under the agreement, Cardinal Health will serve as an authorized distributor of record for Citius Oncology providing specialty pharmaceutical distribution services. About LYMPHIR™ (denileukin diftitox-cxdl) LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors. In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of CTCL and PTCL. Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize LYMPHIR in all markets except for Japan and certain parts of Asia. LYMPHIR was approved by the FDA in August 2024. About Cutaneous T-cell Lymphoma Cutaneous T-cell lymphoma is a type of cutaneous non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type of lymphocyte that plays a role in the immune system, become cancerous and develop into skin lesions, leading to a decrease in the quality of life of patients with this disease due to severe pain and pruritus. Mycosis Fungoides (MF) and Sézary Syndrome (SS) comprise the majority of CTCL cases. Depending on the type of CTCL, the disease may progress slowly and can take anywhere from several years to upwards of ten to potentially reach tumor stage. However, once the disease reaches this stage, the cancer is highly malignant and can spread to the lymph nodes and internal organs, resulting in a poor prognosis. Given the duration of the disease, patients typically cycle through multiple agents to control disease progression. CTCL affects men twice as often as women and is typically first diagnosed in patients between the ages of 50 and 60 years of age. Other than allogeneic stem cell transplantation, for which only a small fraction of patients qualify, there is currently no curative therapy for advanced CTCL. INDICATION LYMPHIR is an IL2-receptor-directed cytotoxin indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. IMPORTANT SAFETY INFORMATION BOXED WARNING: CAPILLARY LEAK SYNDROME Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity. WARNINGS AND PRECAUTIONS Capillary Leak Syndrome LYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin <3 g/dL. These symptoms were not required to occur simultaneously to be characterized as capillary leak syndrome. As defined, CLS occurred in 27% of patients in the pooled population across 3 clinical trials, including 8% with Grade 3. There was one (0.8%) fatal occurrence of CLS. Of the patients with CLS, 22% had recurrence. The majority of CLS events (81%) occurred within the first 2 cycles of treatment. The median time to onset from Cycle 1, Day 1 was 6.5 days (range: 1 to 77), the median duration of CLS was 14 days (range: 2 to 40), and 75% of patients had resolution. The most common symptoms included edema, hypoalbuminemia, and hypotension. Pleural effusion, pericardial effusion, and dehydration also occurred. Regularly assess patients for weight gain, new onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum albumin levels prior to the initiation of each cycle of therapy and more often as clinically indicated. Withhold, reduce dose, or permanently discontinue based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when serum albumin is greater than or equal to 3 g/dL. Visual Impairment LYMPHIR can cause serious visual impairment, including changes in visual acuity and color vision. In the pooled population across 3 clinical trials, visual impairment occurred in 9%, with Grade 1 in 8% and Grade 2 in 1%. The most commonly reported symptom was blurred vision. Of the patients with visual impairment, 67% had resolution of their visual impairment. Perform baseline ophthalmic examination and monitor as clinically indicated. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, or blurred vision, refer for ophthalmologic evaluation. Withhold LYMPHIR until visual impairment resolves or permanently discontinue based on severity. Infusion-Related Reactions LYMPHIR can cause serious infusion-related reactions. Infusion-related reactions were reported in 69% of patients in the pooled population across 3 clinical trials of patients who received LYMPHIR, with Grade 3 infusion-related reactions in 3.4% [see Adverse Reactions (6.1)]. Eighty-three percent of infusion-related reactions occurred in Cycles 1 and 2. The most common symptoms included nausea, fatigue, chills, musculoskeletal pain, vomiting, fever, and arthralgia. Premedicate patients for the first three cycles prior to starting a LYMPHIR infusion [see Dosage and Administration (2.3)]. Monitor patients frequently during infusion. For Grade 2 or higher infusion reactions, premedicate at least 30 minutes prior to each subsequent infusion with a systemic steroid for at least 3 cycles. Interrupt or discontinue LYMPHIR based on severity [see Dosage and Administration (2.4)]. Institute appropriate medical management. Hepatotoxicity LYMPHIR can cause hepatotoxicity. In the pooled safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients, with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median time to onset was 8 days (range: 1 to 15 days); median time to resolution was 15 days (range: 7 to 50 days); all cases of Grade 3 ALT or AST elevations resolved [see Adverse Reactions (6.1)]. Elevated total bilirubin occurred in 5% of patients, with Grade 3 occurring in 0.9%. Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold, reduce dose, or permanently discontinue LYMPHIR based on severity. Embryo-Fetal Toxicity Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the initiation of LYMPHIR. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment and for 7 days following the last dose of LYMPHIR. ADVERSE REACTIONS The most common adverse reactions (≥20%), including laboratory abnormalities, are increased transaminases, albumin decreased, nausea, edema, hemoglobin decreased, fatigue, musculoskeletal pain, rash, chills, constipation, pyrexia, and capillary leak syndrome USE IN SPECIFIC POPULATIONS Pregnancy Risk SummaryBased on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. There are no available data on the use of LYMPHIR in pregnant women to evaluate for a drug-associated risk. No animal reproductive and developmental toxicity studies have been conducted with denileukin diftitox. Denileukin diftitox-cxdl causes depletion of regulatory T lymphocytes (Treg), immune activation, and capillary leak syndrome, compromising pregnancy maintenance. Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively. Lactation Risk SummaryNo data are available regarding the presence of denileukin diftitox-cxdl in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with LYMPHIR and for 7 days after the last dose. Females and Males of Reproductive Potential Based on its mechanism of action, LYMPHIR can cause fetal harm when administered to a pregnant woman. Pregnancy TestingVerify the pregnancy status of females of reproductive potential prior to initiating LYMPHIR. Contraception FemalesAdvise females of reproductive potential to use effective contraception during treatment with LYMPHIR and for 7 days after the last dose. Infertility MalesBased on findings in rats, male fertility may be compromised by treatment with LYMPHIR. The reversibility of the effect on fertility is unknown. Pediatric UseSafety and effectiveness of LYMPHIR in pediatric patients have not been established. Geriatric UseOf the 69 patients with Stage I-III r/r CTCL who received LYMPHIR, 34 patients (49%) were 65 years of age and older and 10 patients (14%) were 75 years of age and older. Clinical studies of LYMPHIR did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients. You may report side effects to the FDA at 1-800-FDA-1088 or You may also report side effects to Citius Pharmaceuticals at 1-844-459-6744. Please read Important Safety Information and full Prescribing Information, including Boxed WARNING, for LYMPHIR. About Citius Oncology, Inc. Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit About Citius Pharmaceuticals, Inc. Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Pharma or Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; our need for substantial additional funds; our ability to successfully implement and maintain distribution agreements with current or other future distribution partners; potential disruptions or performance issues involving third-party logistics providers; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission ("SEC") filings which are available on the SEC's website at including in Citius Oncology's and Citius Pharma's Annual Reports on Forms 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allenir@ 908-967-6677 x113 Media Contact: STiR-communicationsGreg SalsburgGreg@ View original content to download multimedia: SOURCE Citius Pharmaceuticals, Inc.

The Vitamin Shoppe's Health & Wellness Trend Report 2025 Highlights Five Key Growth Drivers in Functional Nutrition, Longevity Science, and Supplement Innovation
The Vitamin Shoppe's Health & Wellness Trend Report 2025 Highlights Five Key Growth Drivers in Functional Nutrition, Longevity Science, and Supplement Innovation

Yahoo

timean hour ago

  • Yahoo

The Vitamin Shoppe's Health & Wellness Trend Report 2025 Highlights Five Key Growth Drivers in Functional Nutrition, Longevity Science, and Supplement Innovation

New data reveals what's shaping wellness trends today, from advancements in NAD+ and peptides for sport performance to the explosion of on-the-go protein and new supplement delivery formats SECAUCUS, N.J., June 9, 2025 /PRNewswire/ -- The Vitamin Shoppe®, a national omni-channel specialty retailer of nutritional products, today unveiled its Health & Wellness Trend Report 2025, an in-depth, data-driven look at the evolving priorities, preferences, and behaviors shaping the wellness industry. Now in its fourth year, the report combines proprietary sales and search insights from over 635 retail locations and industry-wide data from SPINS; and analysis from a newly commissioned survey of 2,000 U.S. adults, conducted by leading market research firm Talker Research. The report reveals a modern wellness consumer who is highly engaged, informed, and innovation-driven: 69% of Americans take dietary supplements to support personal health goals, which include improving energy (49%), immunity (38%), cognitive function (37%), and bone health (35%). 66% are actively trying to consume more protein, driving growth in new on-the-go formats that prioritize taste and convenience. 35% already use AI to manage or learn about their health, for activities such as planning meals, researching health conditions, and learning about supplement routines. Another 27% are considering doing so. While social media is often credited for driving wellness trends, traditional information sources still hold significant sway: 15% cite TikTok as a source of discovery, but 30% cite friends, 29% news media, and 21% ads. Genuine trust still lies with credentialed experts—59% of respondents rate doctors as "very trustworthy," compared to only 11% for influencers. "At The Vitamin Shoppe, we're here to support every customer on their journey of lifelong wellness, whether they're just starting out or optimizing an established routine," said Sharon Leite, CEO of The Vitamin Shoppe. "Our Health & Wellness Trend Report 2025 offers a clear look at the products, ingredients, and innovations shaping how people care for their health today. This annual report is both a guide for consumers navigating a fast-changing wellness landscape and a strategic resource for brands seeking to stay aligned with evolving consumer attitudes and behaviors." According to the report's findings, the Top Five Health & Wellness Trends in 2025 are: Protein Evolves into Lifestyle NutritionOnce limited mostly to powders in shaker cups, supplemental protein is now a core wellness staple in ready-to-drink beverages, bars, and snacks. At The Vitamin Shoppe, sales of RTD protein drinks rose 20% year-to-date and protein bars and snacks jumped 28%, even as protein powders pulled back 12%. Clear protein drinks (refreshing, rather than creamy), better-for-you snacks, and indulgent macro-balanced bars—like those from Barebells (up 97% YTD) and David (now the #2 bar out of 30 brands at The Vitamin Shoppe)—are helping to drive this shift. NAD+ Goes Mainstream as a Longevity EssentialFueled by social media, marketing buzz, and research breakthroughs, NAD+ (nicotinamide adenine dinucleotide) has become one of the biggest longevity and cellular health trends of the past year. Searches for NAD+ on have skyrocketed 500% this year, while the NAD+ category drove 90% of growth in the fast-expanding cellular health category (which nearly doubled in Q1). The reason? Research shows that NAD+ supplementation can improve overall cellular function, enhancing vitality and healthspan, especially in older people experiencing drops in their natural NAD+ levels. Peptides Redefine Muscle Health and RecoveryUsually associated with beauty and skincare, peptides are emerging as the next big thing in sports nutrition, due to the unique ways they support performance, recovery, and overall muscle health. Searches for peptides are up 550% on this year, fueled by innovations like PeptiStrong®—a patented, plant-based peptide complex developed using AI technology—used in top-performing launches such as AN Performance Creatine + Peptide and Force Factor Anabolic Muscle Builder. Peptides are even addressing muscle preservation for GLP-1 medication users, as in formulas from Whole Health Rx™, illustrating their on-trend, functional potential. Supplement Delivery Formats Get a Modern MakeoverConvenience and experience are driving the rise of liquids, gummies, chews, beadlets, and topicals as alternatives to traditional pills and powders. As consumers look for more enjoyable, personalized ways to consume supplements, liquid vitamins are up 50% this year at The Vitamin Shoppe, with MaryRuth's leading the charge (+90% YTD). Searches for "creatine gummies" have surged 1,300% this year, and new delivery systems like creatine beadlets from BodyTech Elite, transdermal magnesium sprays, and ashwagandha honey sticks are expanding the definition of supplementation. Shilajit Gets a Second Life with a New Generation of Wellness SeekersOnce a niche Ayurvedic remedy, shilajit is trending hard, with Q1 sales up 40% and searches up 52% YTD at The Vitamin Shoppe. The resin-like adaptogen, often sourced in the Himalayas, is rich in fulvic acid and over 80 essential minerals, winning a new generation of wellness seekers enjoying benefits across multiple use cases, such as energy, hormonal health, bone support, and cognition. Marketing-savvy brands like Better Alt and Cymbiotica are innovating beyond shilajit's old-school resin format with easy-to-use capsules, gummies, and honey sticks. "These five top trends outlined in our Health & Wellness Trend Report 2025 reflect a consumer focused on optimizing both daily performance and longer-term healthspan," said Muriel Gonzalez, President of The Vitamin Shoppe. "From the innovation of advanced compounds like peptides and NAD+, to the rising demand for convenient, on-the-go protein formats and enjoyable supplement delivery systems, we're seeing an ongoing shift toward personalized wellness choices that are rooted in scientific efficacy and modern lifestyle integration." To access and download the full Health & Wellness Trend Report 2025, visit The Vitamin Shoppe Press Room. About The Vitamin Shoppe® Lifelong Wellness Starts Here™. The Vitamin Shoppe® is a global, omnichannel specialty retailer and wellness lifestyle Company with the mission of providing customers with the most trusted products, guidance, and services to support them on their journeys of lifelong wellness. Based in Secaucus, New Jersey, the Company offers a comprehensive assortment of nutritional solutions, including vitamins, minerals, sports nutrition, specialty supplements, herbs, homeopathic remedies, and green living products. In addition to carrying products from approximately 700 national brands, The Vitamin Shoppe offers products from its proprietary brands within its owned and wholesale channels, including: The Vitamin Shoppe®, Vthrive The Vitamin Shoppe®, BodyTech®, BodyTech® Elite, plnt®, ProBioCare®, True Athlete®, and Whole Health Rx™. In the U.S., the Company conducts business through over 635 company-operated retail stores under The Vitamin Shoppe and Super Supplements™ banners and via its website, Globally, The Vitamin Shoppe serves customers in select Asia, South America, and Central America markets through local omnichannel partners. View original content to download multimedia: SOURCE The Vitamin Shoppe

Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting
Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting

Yahoo

timean hour ago

  • Yahoo

Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting

Presentation of Data from Clinical Trial of Aspen's Autologous iPSC-derived Approach for Neuronal Replacement Therapy in Parkinson's Disease SAN DIEGO, June 9, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc. announced its participation in "Illuminating the Future," the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting, to be held in Hong Kong June 11-14. Aspen Co-founder and Senior Vice President, Research and Development, Andrés Bratt-Leal, PhD will deliver a presentation, Safety, tolerability, and efficacy of transplanted autologous iPSC-derived dopaminergic precursors in moderate to advanced Parkinson's Disease. Dr. Bratt-Leal's presentation will cover data for the first four patients of the ASPIRO Study*, a Phase 1/2a trial of the company's iPSC-derived autologous cell therapy (ANPD001). The open label trial was designed to evaluate the safety, tolerability and efficacy of intracranial implantation of autologous induced pluripotent stem cell (iPSC)-derived dopaminergic neuronal precursor cells (DANPCs) in patients with moderate to advanced Parkinson's disease. The primary objective of the ongoing study is to assess safety and tolerability of the procedure. A secondary objective is to evaluate clinical efficacy as measured by change from baseline in multiple patient-reported and clinician-reported Parkinson's disease outcome measures. Continued follow up and evaluation of a higher-dose cohort in the study are ongoing. "Early data from the first four patients show that precision intracranial delivery of DANPCs is safe and well-tolerated," reported Dr. Bratt-Leal. "Both patient-reported and clinician-reported outcomes show early signs of changes from baseline in multiple clinically meaningful outcome measures. Autologous iPSC-derived therapy as a regenerative medicine approach has the unique advantage of not requiring immunosuppressive medications." About Aspen Neuroscience Headquartered in San Diego, Aspen Neuroscience, Inc. is a clinical development-stage, private company focused on autologous regenerative medicine. The company's patient-derived iPSC platform is used to create personalized therapies to address diseases with high unmet medical needs, beginning with autologous neuron replacement for PD. Aspen combines cell biology with the latest machine learning and genomic approaches to investigate patient-specific, restorative cell treatments. The company has developed a best-in-class platform to create and optimize pluripotent-derived cell therapies, which includes in-house bioinformatics, manufacturing and quality control. For more information and important updates, please visit or email media@ * The study was made possible by funding from the California Institute for Regenerative Medicine (CIRM), a state of California Agency that funds regenerative medicine, stem cell, and gene therapy research (Grant Number CLIN2-15547). View original content to download multimedia: SOURCE Aspen Neuroscience, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store